Format

Send to

Choose Destination
Eur J Drug Metab Pharmacokinet. 2002 Jul-Sep;27(3):185-92.

Effect of coenzyme Q10 on the disposition of doxorubicin in rats.

Author information

1
Clinical Pharmacology Unit, Division of Clinical Trials & Epidemiological Sciences, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Republic of Singapore.

Abstract

The effect of exogenous coenzyme Q10 (CoQ10) on the pharmacokinetic profiles and biliary excretion of doxorubicin and its main metabolites, doxorubicinol and doxorubicinolone, was investigated in rats. No statistically significant changes in the pharmacokinetic parameters of doxorubicin was observed following the intravenous bolus administration of 10 mg/kg doxorubicin to rats during a 6-day oral regimen of CoQ10 (20 mg/kg daily). Treatment with CoQ10 did not affect the formation of the doxorubicinol, but produced a 75% increase (P < 0.05) in the AUC of doxorubicinolone. Correspondingly, CoQ10 had no apparent effect on the biliary excretion of doxorubicin and formation clearance of doxorubicinol, whereas the formation clearance of doxorubicinolone was significantly increased by 69% in CoQ10-pretreated rats (P < 0.05). Overall, the results suggest that CoQ10 treatment has no significant effect on the pharmacokinetics of doxorubicin and the formation of the cytotoxic metabolite, doxorubicinol.

PMID:
12365200
DOI:
10.1007/BF03190456
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center